In brief
The UK Health Security Agency announced a study aiming to measure per‑and polyfluoroalkyl substances (PFAS), lead, arsenic and other chemicals in blood and urine samples collected through the Health Survey for England. Initial findings are slated for 2027, with early analysis indicating possible links to raised cholesterol and lower birth weight but limited health effects overall.
The UK Health Security Agency (UKHSA) has announced the launch of a nationwide study to assess human exposure to per‑ and polyfluoroalkyl substances (PFAS) and other hazardous chemicals, including lead and arsenic, and to investigate their potential impact on public health. The research will analyze blood and urine samples from participants in the existing Health Survey for England, a long‑running program that collects biological specimens and health data from a representative sample of the population.
PFAS—often referred to as “forever chemicals” because of their resistance to environmental degradation—are widely used in industrial processes and consumer products. Growing concerns over their persistence and possible adverse effects have spurred authorities worldwide to intensify monitoring and research efforts.
Dr. Edward Wynne‑Evans, UKHSA’s director of radiation, chemicals, climate and environmental hazards, said significant gaps remain in understanding what varying levels of PFAS exposure mean for an individual’s long‑term health.
"The evidence available to date suggests that any health effects are likely to be limited,"
Wynne‑Evans added.
"The strongest evidence currently points to possible associations with raised cholesterol and lower birth weight. However, further research is needed to better understand these findings and their significance."
The study’s assessment will involve quantifying the concentration of PFAS, lead, arsenic and other potential contaminants in biological fluids, then comparing these levels against established reference ranges and health outcome data. UKHSA will collaborate with international partners to keep abreast of emerging evidence and to refine risk assessments as new information becomes available.
Although the preliminary analysis suggests limited health effects, the agency does not yet recommend routine blood testing for PFAS. The lack of a consensus on clinically actionable thresholds leads to uncertainty about what medical action should follow a particular test result, the UKHSA noted.
Initial results are expected in 2027, at which point the agency intends to publish a comprehensive report detailing exposure levels across demographic groups, potential trends over time, and any significant associations with measurable health outcomes such as cholesterol profiles and birth weight. This data will inform future policy decisions, potential screening guidelines and public health interventions aimed at reducing exposure to persistent environmental chemicals.
The Health Survey for England has historically served as a cornerstone for public health surveillance in the United Kingdom, providing essential data on disease prevalence, health behaviors and exposure to environmental hazards. By incorporating PFAS and heavy metals into its analytical framework, the UKHSA is extending the survey’s reach into a domain of growing scientific interest.
The launch of this study underscores the agency’s commitment to evidence‑based risk assessment and reflects international trends toward enhanced chemical monitoring. By systematically measuring pollutant levels in population samples and linking them to health indicators, the research aims to clarify the public health significance of “forever chemicals” and to guide regulatory actions, if warranted, against these persistent pollutants.
